Aadi Bioscience Valuation

Is 3350 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 3350 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 3350 (€1.91) is trading above our estimate of fair value (€0.34)

Significantly Below Fair Value: 3350 is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 3350?

Other financial metrics that can be useful for relative valuation.

3350 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Sales Ratio vs Peers

How does 3350's PS Ratio compare to its peers?

The above table shows the PS ratio for 3350 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average6.3x
2INV 2invest
7.7xn/a€59.8m
HPHA Heidelberg Pharma
13.4x16.6%€114.2m
MDG1 Medigene
3.2x16.1%€23.0m
CNW co.don
0.7xn/a€6.5m
3350 Aadi Bioscience
2.1x38.8%€51.8m

Price-To-Sales vs Peers: 3350 is good value based on its Price-To-Sales Ratio (2.1x) compared to the peer average (8.1x).


Price to Earnings Ratio vs Industry

How does 3350's PE Ratio compare vs other companies in the DE Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a39.4%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a39.4%
n/an/an/a
No more companies

Price-To-Sales vs Industry: 3350 is good value based on its Price-To-Sales Ratio (2.1x) compared to the European Biotechs industry average (8.5x).


Price to Sales Ratio vs Fair Ratio

What is 3350's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

3350 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.1x
Fair PS Ratio1.3x

Price-To-Sales vs Fair Ratio: 3350 is expensive based on its Price-To-Sales Ratio (2.1x) compared to the estimated Fair Price-To-Sales Ratio (1.3x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 3350 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€1.91
€1.75
-8.5%
6.7%€1.86€1.63n/a2
Nov ’25€1.82
€1.47
-19.4%
7.7%€1.58€1.35n/a2
Oct ’25€1.82
€1.47
-19.4%
7.7%€1.58€1.35n/a2
Sep ’25€1.55
€5.14
+231.7%
101.5%€12.52€1.34n/a3
Aug ’25€1.41
€10.20
+623.5%
38.6%€12.98€4.64n/a3
Jul ’25€1.35
€10.20
+655.7%
38.6%€12.98€4.64n/a3
Jun ’25€1.61
€10.20
+533.6%
38.6%€12.98€4.64n/a3
May ’25€1.71
€10.72
+526.7%
41.0%€14.70€4.59n/a3
Apr ’25€2.18
€10.72
+391.6%
41.0%€14.70€4.59n/a3
Mar ’25€1.79
€10.70
+497.9%
41.0%€14.68€4.59n/a3
Feb ’25€1.67
€10.70
+540.8%
41.0%€14.68€4.59n/a3
Jan ’25€1.87
€10.70
+472.3%
41.0%€14.68€4.59n/a3
Dec ’24€4.74
€30.84
+550.5%
6.4%€33.64€28.03n/a4
Nov ’24€4.08
€33.66
+725.1%
16.3%€42.98€28.65€1.824
Oct ’24€4.62
€32.12
+595.2%
16.3%€41.00€27.33€1.824
Sep ’24€5.75
€32.12
+458.5%
16.3%€41.00€27.33€1.554
Aug ’24€4.78
€32.29
+575.4%
16.3%€41.22€27.48€1.414
Jul ’24€6.30
€32.29
+412.5%
16.3%€41.22€27.48€1.354
Jun ’24€7.40
€32.29
+336.3%
16.3%€41.22€27.48€1.614
May ’24€7.15
€36.46
+409.9%
17.0%€43.11€27.52€1.714
Apr ’24n/a
€36.67
0%
17.0%€43.36€27.68€2.184
Mar ’24€9.93
€39.61
+298.8%
17.2%€44.74€27.96€1.794
Feb ’24€11.39
€39.22
+244.4%
17.2%€44.30€27.69€1.674
Jan ’24€11.59
€41.05
+254.3%
17.2%€46.36€28.97€1.874
Dec ’23€12.59
€41.05
+226.0%
17.2%€46.36€28.97€4.744
Nov ’23€12.74
€42.22
+231.4%
18.6%€49.50€29.12€4.084

Analyst Forecast: Target price is lower than the current share price.


Discover undervalued companies